Rivastigmine Transdermal System
Study 2018-2030
Phase 3 small_molecule completed
Quick answer
Rivastigmine Transdermal System for Parkinson Disease is a Phase 3 program (small_molecule) at United Therapeutics Europe Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- United Therapeutics Europe Ltd
- Indication
- Parkinson Disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed